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Abstract objectives To identify factors inﬂuencing mortality in an HIV programme providing care to large
numbers of injecting drug users (IDUs) and patients co-infected with hepatitis C (HCV).
methods A longitudinal analysis of monitoring data from HIV-infected adults who started antiret-
roviral therapy (ART) between 2003 and 2009 was performed. Mortality and programme attrition rates
within 2 years of ART initiation were estimated. Associations with individual-level factors were assessed
with multivariable Cox and piece-wise Cox regression.
results A total of 1671 person-years of follow-up from 1014 individuals was analysed. Thirty-four
percent of patients were women and 33% were current or ex-IDUs. 36.2% of patients (90.8% of IDUs)
were co-infected with HCV. Two-year all-cause mortality rate was 5.4 per 100 person-years (95% CI,
4.4–6.7). Most HIV-related deaths occurred within 6 months of ART start (36, 67.9%), but only 5
(25.0%) non-HIV-related deaths were recorded during this period. Mortality was higher in older
patients (HR = 2.50; 95% CI, 1.42–4.40 for ‡40 compared to 15–29 years), and in those with initial
BMI < 18.5 kg⁄m
2 (HR = 3.38; 95% CI, 1.82–5.32), poor adherence to treatment (HR = 5.13; 95%
CI, 2.47–10.65 during the second year of therapy), or low initial CD4 cell count (HR = 4.55; 95% CI,
1.54–13.41 for <100 compared to ‡100 cells⁄ll). Risk of death was not associated with IDU status
(P = 0.38).
conclusion Increased mortality was associated with late presentation of patients. In this programme,
death rates were similar regardless of injection drug exposure, supporting the notion that satisfactory
treatment outcomes can be achieved when comprehensive care is provided to these patients.
keywords antiretroviral therapy, cohort study, HIV, injecting drug use, mortality, risk factor
Introduction
By the end of 2009 approximately, 740 000 people were
living with HIV and AIDS in China (Ministry of Health of
the People’s Republic of China 2010). Although the
national HIV prevalence is estimated at 0.06% (Ministry
of Health of the People’s Republic of China 2010), large
disparities are observed both regionally and within differ-
ent population groups: more than 50% of HIV-infected
individuals live in only ﬁve of China’s 22 Chinese
provinces, and HIV prevalence rates of more than 50% are
observed among injecting drug users (IDUs) in some
prefectures and cities (Ministry of Health, People’s
Republic of China, Joint United Nations Programme on
HIV⁄AIDS, and World Health Organization 2010). In
2003, China launched its National Antiretroviral Therapy
(ART) Program and started implementing the ‘Four Frees
and One Care’ policy, which included the provision of free
blood testing, screening and therapy for pregnant women
and education for orphans born of HIV-infected parents.
At the end of that year, the Chinese Center for Disease
Control and Prevention, in collaboration with Me ´decins
Sans Frontie `res (MSF), started a comprehensive HIV
programme in Guangxi province, where HIV prevalence is
estimated at 0.08% in the general population (National
Center for AIDS⁄STD Control and Prevention 2011), and
at 25% among IDUs (Liu et al. 2006).
Injection of illicit drugs is an important mode of HIV
transmission in the region and ensuring access to and
provision of optimal care to this high-risk group is a major
challenge (Celentano et al. 2001; Gebo et al. 2005). An
additional complication is that co-infection of HIV and
hepatitis C virus (HCV) is very common in Guangxi,
especially among heroin users. In one longitudinal cohort
of 547 IDUs, the prevalence of HCV was 17.6% overall
and 95.1% in HIV-infected individuals (Garten et al.
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develop chronic infection (Te & Jensen 2010), which is
associated with increased risk of liver failure and hepato-
cellular carcinoma (Nelson et al. 2011). 3–11% of
individuals with chronic infection will develop liver
cirrhosis within 20 years (Dore et al. 2002). Furthermore,
evidence suggests that HIV infection can accelerate HCV-
related disease progression and mortality (Benhamou et al.
1999; Mohsen et al. 2003; Smit et al. 2008).
In this paper, we describe trends in patient characteris-
tics, all-cause mortality and causes of death in an HIV
programme providing care for a large number of IDUs and
patients co-infected with HCV. We also report on risk
factors inﬂuencing mortality, including history of injecting
drug use, and on whether causes of death differed
according to length of time receiving ART.
Methods
The Guangxi CDC⁄MSF HIV programme
The Guangxi CDC⁄MSF HIV programme offered a com-
bination of HIV counselling and testing, comprehensive
HIV care for HIV positive patients and training for health
professionals. Speciﬁc interventions to improve access to
care for high-risk groups included targeted prevention
outreach activities and referral for HIV testing, training of
staff in prisons and detoxiﬁcation centres, work with peer
groups, and referral of IDUs to methadone and needle
and syringe programmes.
Free HIV care, including combined ART, hospitalisation
costs and psychosocial and nutritional support, was
provided. Financial support for patient transport was also
offered under speciﬁc circumstances. A strong emphasis
was placed on the counselling component of the pro-
gramme before ART initiation and also in the early stages
of treatment. The provision of psychosocial support was
enhanced in 2007 when counsellors from the Red Ribbon
Center joined the team.
Patients were eligible for ART when either the CD4
cell count was <200 cells⁄ll or their disease had reached
WHO clinical stage 3 or 4. In 2009, The CD4 threshold for
ART initiation was increased to <350 cells⁄ll. The most
widely prescribed ﬁrst-line ART regimen contained two
nucleoside reverse transcriptase drugs (NRTI) and one
non-NRTI (NNRTI). Protease-inhibitor second-line regi-
mens were available for patients diagnosed with treatment
failure. CD4 cell counts were measured every 6 months
and viral load testing was performed when treatment
failure was suspected (WHO 2006 criteria). Cotrimoxazole
prophylaxis was provided to patients with CD4 cell count
below 200 cells⁄ll.
Patients who missed a clinical appointment were con-
tacted by phone. During the handover phase of the
programme (from January to September 2010), concerted
efforts were made to ascertain outcomes of patients lost to
care.
Study population and data collection
All patients aged 15 years or older who initiated ART in
the programme between 1 December 2003 and 31
December 2009 were included in the analysis. Programme
data collected until 31 October 2010 were analysed.
Clinicians collected socio-demographic, clinical and
treatment information at each patient visit using standar-
dised questionnaires, and data were entered daily into the
FUCHIA software (Epicentre, Paris). An active search of
patients lost to follow-up was performed before closure of
the programme. For patients who died during follow-up,
two physicians retrospectively determined the cause of
death after reviewing all available medical records. The
primary cause of death was classiﬁed into one of the
following categories: infectious, hepatic, non-hepatic
malignancy, other or unknown. Deaths were further
grouped into HIV-related (i.e. the primary cause of death
was a WHO AIDS-deﬁning condition), non-HIV-related
or unknown.
Lost to follow-up was deﬁned as missing an appointment
by more than 3 months on the date of analysis. Initial
haemoglobin, CD4 cell count and body mass index (BMI)
were deﬁned as the measurement recorded closest to ART
start (between 3 months before and 1 month after this
date).
Statistical methods
Standard basic statistics were used to describe patient
characteristics at ART start per year of ART inclusion.
Because the risk of AIDS-deﬁning conditions potentially
leading to death is higher during the ﬁrst 6 months after
ART start (Martinez et al. 2007), causes of death within
and after 6 months were described separately.
Kaplan–Meier naı ¨ve methods were used to estimate the
probability of death and programme attrition (deaths and
lost-to-follow-up) at 6 months, 1 and 2 years after ART
initiation. The incidences of all-cause, AIDS-related and
non-AIDS-related mortality were estimated by time-
to-event analysis.
Risk factors associated with 2-year mortality were
studied using multivariable Cox’s regression models.
Factors studied included sex, age (5–29, 30–39,
‡40 years), IDU status (current or history of IDU, never
IDU), history of ART use, tuberculosis (TB) diagnosis,
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missing, kg⁄m
2), CD4 cell count (‡100, <100, missing,
cells⁄ll) and haemoglobin (‡11, <11, missing, g⁄dl) at
ART start; year of therapy initiation (2003–2005, 2006–
2007, 2008–2009); and a recently validated marker for
treatment adherence based on the proportion of clinical
appointments attended with no delay over the 2 years of
study follow-up (>95%, £95%) (Pujades-Rodriguez et al.
2010).
The proportional hazards assumption was tested by
plotting scaled Schoenfeld residuals against time (Gram-
bsch & Therneau 1994). Factors for which this assumption
did not hold (IDU status, initial CD4 cell count and
adherence) were analysed by ﬁtting piece-wise Cox’s
models (Collett 1994) to obtain stratum-speciﬁc estimates
of hazard ratio for the periods 0–6 months, 6–12 and
12–24 months of follow-up.
Multivariable analyses were performed in two steps.
First, factors associated with the outcome in univariate
analyses (P < 0.1) were included in a transition model. The
ﬁnal model was then obtained after reintroducing each
non-signiﬁcant factor to assess whether it induced at least a
10% change in the estimated adjusted hazard ratios (aHR).
Associations were assessed using likelihood ratio tests.
Two-sided P-values <0.05 were considered statistically
signiﬁcant. Two sensitivity analyses were performed. First,
multivariable analyses were repeated using attrition as the
main outcome. Second, we performed complete case
analyses excluding individuals with missing BMI and CD4
cell count data. All analyses were done in Stata 11.0
(StataCorps, TX, USA).
Results
Patient characteristics at ART initiation
A total of 1014 adults started ART during the study period
and contributed 1671 person-years of follow-up. Thirty-
four percent were women, and median age at therapy
initiation was 34 years (Table 1). Thirty-three percent
were currently IDUs or had a history of injecting drug use.
Results of HCV antibody testing in 898 patients showed
that 325 (36.2%) were positive (90.8% of IDUs), while
hepatitis B surface antigen test results from 952 patients
showed 15% to be positive (92.8% of the IDU patients
tested).
At ART start, median time since programme entry was
1 month [IQR 0.5–3.0]. The proportion of patients with
initial clinical stage 3 or 4 decreased over time from 82.8%
in 2003–2004 to 49.6% in 2009, and median CD4 cell
count gradually increased from 53 to 167 cells⁄ll. The
most commonly prescribed ART regimen, except during
2006–2007, was AZT-based, and 80% of patients
achieved good adherence during the ﬁrst 2 years of ART
use (index category ‡95%).
Mortality and causes of death
A total of 91 (9.0%) patients died during the ﬁrst 2 years
of ART use. This ﬁgure includes 53 (58.2%) deaths from
AIDS-related causes, 20 (22.0%) from non-AIDS-related
conditions and unknown causes of death for the remaining
18 patients (Table 2). The Kaplan–Meier probability of
death at 2 years was 10.0% (95% CI, 8.2–12.2%;
Figure 1), which corresponds to an all-cause mortality rate
of 5.4 per 100 person years (95% CI, 4.4–6.7). Mortality
was highest during the 6 months after ART start, with
9.68 deaths per 100 person years (95% CI, 7.27–12.88),
and fell thereafter (to 2.63 per 100 person-years, 95% CI,
1.50–4.64 in the 6- to 12-month period; and 4.39 per
person years; 95% CI, 3.10–6.20 in 12–24 months).
The majority of AIDS-related deaths also occurred
within the ﬁrst 6 months of ART (36, 67.9%), while only
5 (25.0%) non-AIDS-related deaths during the same time
period. Sixty-eight percent of deaths from known causes
were attributed to infections, 8 (12.9%) to malignancies,
6 (9.7%) to hepatic disease and 6 (9.7%) to other causes.
For 30%, the cause of death could not be determined
(Figure 2).
Programme attrition
The vital status of 27 (2.7%) patients lost to follow-up
could not be determined and 52% were lost within the ﬁrst
3 months of therapy. The Kaplan–Meier probability
of attrition was 6.3% (95% CI, 5.0–8.0) at 6 months,
8.1% (95% CI, 6.5–9.9%) at 1 year and 12.7% (95% CI,
10.7–15.0%) at 2 years of ART start (Figure 1). The
overall attrition rate was 7.06 per 100 person years (95%
CI, 5.90–8.46). It was highest in the 0- to 6-month period
(13.18 per 100 person years; 95% CI, 10.31–16.84) and
dropped thereafter (3.73 per 100 person-years, 95% CI,
2.32–6.00 in the 6-to 12-month period; and 5.07 per 100
person-years; 95% CI, 3.67–7.00 in the 12- to 24-month
period; Table 2).
Risk factors for death and programme attrition
Multivariable analyses showed increased mortality in
patients aged ‡40 years (aHR = 2.50; 95% CI, 1.42–4.40)
and in those with BMI < 18.5 kg⁄m
2 (aHR = 3.11; 95%
CI, 1.82–5.32; Table 3). Poor adherence and CD4 cell
count <100 cells⁄ll or unknown were also associated with
higher mortality. The effect of adherence increased with
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1258 ª 2012 Blackwell Publishing Ltdlonger treatment duration, so that no difference in
mortality between compliant and non-compliant patients
was observed during the ﬁrst 6 months of ART
(aHR = 1.02; 95% CI, 0.48–2.15), but mortality ratios
for poor vs. good adherence subsequently increased
(aHR = 14.38; 95% CI, 3.80–54.44 for the 6- to 12-
month period; and aHR = 5.13; 95% CI, 2.47–10.65
during the second year of therapy). In contrast, the effect
of initial CD4 cell counts was seen only during the ﬁrst
6 months of ART (aHR = 4.55; 95% CI, 1.54–13.41 for
patients with CD4 cell count <100 cells⁄ll compared to
‡100 cells⁄ll).
The effect of previous or current intravenous drug use
was also time dependent in univariate analyses, with higher
mortality observed among IDUs compared with non-IDUs
during the second year of ART (HR = 2.33; 95% CI, 1.17–
4.67). Nevertheless, this effect disappeared after adjusting
for other risk factors, namely sex and age. Adjusting for
differences in adherence levels between these two groups
did not change the estimates (data not shown).
Risk factors associated with attrition were similar to
those described for mortality, but generally of lower
magnitude (Table S1). Analyses restricted to patients with
complete clinico-immunological data identiﬁed identical
risk factors (Table 3).
Discussion
InthisHIVprogrammewithalargeproportionofcurrentor
ex-IDUs in the Nanning province, 88% of patients were
aliveandreceivingHIVcare2 yearsafterstartingART;only
9% had died. Mortality was highest during the initial
6 months of treatment, with 68% of deaths being AIDS-
related, and most commonly from an infection-related
cause. With longer follow-up on ART, the proportion of
deaths related to AIDS decreased but non-AIDS-related
deaths(i.e.cancerorhepaticdisease)becamemorecommon.
Table 2 Mortality and attrition rates stratiﬁed by period of
follow-up on ART
No. of
deaths
Person-years
of
follow-up
Mortality per
100 person-years
(95% CI)
All-cause mortality
At 6 months 47 485.65 9.68 (7.27–12.88)
At 1 year 12 455.92 2.63 (1.50–4.64)
At 2 years 32 729.51 4.39 (3.10–6.20)
Total 91 1671.08 5.44 (4.43–6.69)
AIDS-related mortality
At 6 months 36 485.65 7.41 (5.34–10.28)
At 1 year 4 455.92 0.88 (0.33–2.34)
At 2 years 13 729.51 1.78 (1.03–3.07)
Total 53 1671.08 3.17 (2.42–4.15)
Non-AIDS-related mortality
At 6 months 5 485.65 1.03 (0.43–2.47)
At 1 year 5 455.92 1.10 (0.46–2.63)
At 2 years 10 729.51 1.37 (0.74–2.55)
Total 20 1671.08 1.20 (0.77–1.86)
Attrition
At 6 months 64 485.65 13.18 (10.31–16.84)
At 1 year 17 455.92 3.73 (2.32–6.00)
At 2 years 37 729.51 5.07 (3.67–7.00)
Total 118 1671.08 7.06 (5.90–8.46)
CI, conﬁdence interval.
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Figure 1 Kaplan–Meier cumulative probabilities of death, loss
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No. of
deaths
Person-
years
Rate per 100
person-years
(95% CI)
Crude HRR
(95% CI)
Adjusted HR
from model 1
(95% CI)
Adjusted HR from
model 2 (95% CI)
Age group, years P = 0.002 P = 0.004 P = 0.173
15–29 22 512.4 4.3 (2.8–6.5) 1.00 1.00 1.00
30–39 27 682.3 4.0 (2.7–5.8) 0.92 (0.53–1.62) 0.94 (0.52–1.68) 1.04 (0.51–2.13)
‡40 42 476.4 8.8 (6.5–11.9) 2.03 (1.21–3.41) 2.50 (1.42–4.40) 1.79 (0.88–3.63)
Sex P < 0.001 P = 0.065 P = 0.222
Women 16 570.8 2.8 (1.7–4.6) 1.00 1.00 1.00
Men 75 1100.3 6.8 (5.4–8.5) 2.43 (1.42–4.16) 1.71 (0.95–3.10) 1.79 (0.90–3.56)
History of ART exposure P = 0.095 P = 0.132
No 86 1494 5.8 (4.7–7.1) 1.00 1.00
Yes 5 177.1 2.8 (1.2–6.8) 0.50 (0.20–1.23) 0.51 (0.20–1.32)
Year of ART start P = 0.954
2003–2005 26 464.3 5.6 (3.8–8.2) 1.00
2006–2007 33 614.9 5.4 (3.8–7.5) 0.96 (0.57–1.61)
2008–2009 32 591.9 5.4 (3.8–7.6) 0.92 (0.55–1.55)
Clinical stage P < 0.001 P = 0.078
1 or 2 14 570.2 2.5 (1.5–4.1) 1.00 1.00
3 24 510.8 4.7 (3.1–7.0) 1.93 (1.00–3.73) 0.76 (0.36–1.61)
4 53 590.1 9.0 (6.9–11.8) 3.70 (2.05–6.67) 1.34 (0.65–2.78)
Tuberculosis diagnosis P = 0.001 P = 0.079 P = 0.158
No 57 1293.2 4.4 (3.4–5.7) 1.00 1.00 1.00
Yes 34 377.9 9.0 (6.4–12.6) 2.05 (1.34–3.14) 1.53 (0.96–2.45) 1.57 (0.85–2.91)
BMI, kg⁄m
2 P < 0.001 P < 0.001 P < 0.001
‡18.5 21 935 2.2 (1.5–3.4) 1.00 1.00 1.00
<18.5 47 604.4 7.8 (5.8–10.3) 3.50 (2.09–5.85) 3.11 (1.82–5.32) 3.38 (1.85–6.18)
Unknown 23 131.7 17.5 (11.6–26.3) 7.63 (4.22–13.79) 7.04 (3.80–13.03) NA
Haemoglobin, g⁄dl P = 0.172 P = 0.589
‡11 43 949.3 4.5 (3.4–6.1) 1.00 1.00
<11 41 630.1 6.5 (4.8–8.8) 1.45 (0.94–2.22) 0.83 (0.51–1.33)
Unknown 7 91.6 7.6 (3.6–16.0) 1.68 (0.75–3.73) 1.29 (0.50–3.00)
No. of
deaths
Person-
years
Rate per 100
person-years
(95% CI)
Unadjusted HRR
(95% CI)
Adjusted HR
from model 1
(95% CI)
Adjusted HR from
model 2 (95% CI)
IDU Status P = 0.116 P = 0.380
0–6 months
Never 33 324.7 10.2 (7.2–14.3) 1.00 1.00
Ever 14 161 8.7 (5.2–14.7) 0.86 (0.46–1.60) 0.78 (0.40–1.52)
6–12 months
Never 8 304.9 2.6 (1.3–5.2) 1.00 1.00
Ever 4 151 2.6 (1.0–7.1) 1.01 (0.30–3.36) 0.59 (0.17–2.03)
12–24 months
Never 15 490.6 3.1 (1.8–5.1) 1.00 1.00
Ever 17 238.9 7.1 (4.4–11.4) 2.33 (1.17–4.67) 1.60 (0.75–3.41)
CD4 cell count, cells⁄ll P < 0.001 P = 0.040 P = 0.060
0–6 months
‡100 4 186.2 2.1 (0.8–5.7) 1.00 1.00 1.00
<100 31 196.4 15.8 (11.1–22.4) 7.32 (2.59–20.75) 4.55 (1.54–13.41) 3.62 (1.22–10.75)
Unknown 12 103.1 11.6 (6.6–20.5) 5.42 (1.75–16.79) 3.34 (1.04–10.76) –
6–12 months
‡100 3 174.9 1.7 (0.6–5.3) 1.00 1.00 1.00
<100 7 185.2 3.8 (1.8–7.9) 2.21 (0.57–8.56) 1.55 (0.39–6.19) 1.34 (0.31–5.73)
Unknown 2 95.9 2.1 (0.5–8.3) 1.21 (0.20–7.25) 0.64 (0.10–3.99) –
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mortality and programme attrition.
Success of the comprehensive, patient cost-free model of
care implemented in Nanning was reﬂected in the high
programme retention rate achieved, 91.9% one year after
ART start and 87.3% after 2 years. These ﬁgures are
higher than overall retention estimates from 13 Asian HIV
programmes, 80.2% and 68.7% at 12 and 24 months,
respectively (Tassie et al. 2010). Furthermore, although the
percentage of HIV patients who enter care with a CD4
count <50 cells⁄ll in China has remained relatively
constant at 25% since 2006 (Dou et al. 2010), in our
programme, this proportion decreased over time, most
likely as a result of intensive efforts to improve access to
HIV testing and care in the area. Still, one in two patients
treated in Nanning presented with advanced HIV disease,
indicating that further efforts are still needed to diagnose
and treat HIV patients at earlier stages of infection.
Intensive efforts to trace patients lost to follow-up and to
ascertain mortality in the months before handover of the
programme, and low rates of loss to follow-up, contributed
tothelowmortalityobservedduringtheﬁrst2 yearsofART
(9% of patients). This estimate is lower than mortality
reported in an HIV programme in Phnom Penh, Cambodia
[12.7% (Ferradini et al. 2007)] and similar to published
aggregated national ﬁgures from China (Zhang et al. 2009).
As previously reported (Coetzee et al. 2004; Braitstein et al.
2006;Zachariahet al.2006),highermortalitywasobserved
during the ﬁrst 6 months of ART (9.68 deaths per 100
personyearsintheﬁrst6 monthsonART).Notsurprisingly,
the majority of deaths recorded during this time period
were AIDS-related (68%) and, with longer ART use and
improved immune function, the proportion of these deaths
decreased. Although the primary cause of death was classi-
ﬁedretrospectivelyinthisstudyandcouldnotbedetermined
for approximately 20% of patients, and because the
proportion of deaths from unknown causes increased with
time on ART, misclassiﬁcations of causes are unlikely to be
related to treatment duration. Furthermore, reports of
changes in the distribution of causes of death over time have
also being described in other cohorts in resource-rich
countries (2010; Bonnet et al. 2002).
Factors associated with mortality in this HIV programme
weremalesex,ageolderthan40 years,lowinitialBMIanda
diagnosis of TB at therapy start, all known from previous
studies to be important risk factors for HIV progression and
death. Unsurprisingly, patients with poor adherence rates
(especially in the longer-term) and those who initiated ART
at low CD4 counts were also at a higher risk of death.
A large proportion of the patients treated in the
programmewereknownex-orcurrentIDUs,andmanywere
co-infected with hepatitis C and B (38% and 15% of
patients, respectively). Provision of HIV care to IDUs is
challenging. Barriers to accessing care, including national
drug policies and strategies that lead to marginalisation of
IDUs (Rhodes et al. 2003; Wood et al. 2007), along with
social instability and homelessness (Bassetti et al. 1999;
Chanderet al.2006;Knowltonet al.2006)andwithpatient
(Bassetti et al. 1999; Kerr et al. 2005) or physician (Bassetti
et al. 1999; Gross et al. 2002) reluctance to start ART
Table 3 (Continued)
No. of
deaths
Person-
years
Rate per 100
person-years
(95% CI)
Unadjusted HRR
(95% CI)
Adjusted HR
from model 1
(95% CI)
Adjusted HR from
model 2 (95% CI)
12–24 months
‡100 10 276.5 3.6 (1.9–6.7) 1.00 1.00 1.00
<100 12 318 3.8 (2.1–6.6) 1.04 (0.45–2.40) 0.72 (0.29–1.75) 0.78 (0.30–2.03)
Unknown 10 135.1 7.4 (4.0–13.8) 2.07 (0.86–4.96) 1.10 (0.42–2.89) –
Treatment adherence P < 0.001 P < 0.001 P < 0.001
0–6 months
‡95% 38 388.8 9.8 (7.1–13.4) 1.00 1.00 1.00
<95% 9 96.9 9.3 (4.8–17.9) 0.95 (0.46–1.96) 1.02 (0.48–2.15) 0.95 (0.36–2.52)
6–12 months
‡95% 3 367.5 0.8 (0.3–2.5) 1.00 1.00
<95% 9 88.5 10.2 (5.3–19.6) 12.33 (3.34–45.54) 14.38 (3.80–54.44)
12–24 months
‡95% 14 601.4 2.3 (1.4–3.9) 1.00 1.00 1.00
<95% 18 128.1 14.0 (8.8–22.3) 6.14 (3.05–12.35) 5.13 (2.47–10.65) 4.49 (1.77–11.35)
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; HR, hazard rate ratio; IDU, injecting drug user; model 1
includes all eligible patients; model 2 includes only eligible patients with initial BMI and CD4 cell count data.
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adherent and⁄or might develop and transmit ART-resistant
virus (Wainberg & Friedland 1998; Ding et al. 2005; Mills
et al. 2006) have been well described (Wood et al. 2008b).
Yet, despitethesechallenges,IDUstreatedintheNanning
comprehensive care programme did not experience higher
mortality or attrition rates than other patients during their
ﬁrst 2 years of ART. Even if the patients treated in the
Nanning programme may not represent the general IDU
population, IDUs might be more likely to experience
accidental death from non-HIV-related causes such as drug
overdose (Wood et al. 2008a). Furthermore, the lack of a
difference in mortality regardless of IDU status is consistent
with evidence from a Canadian study reporting similar all-
cause mortality and non-accidental mortality in HIV-
infected IDUs and non-IDUs treated with ART for
84 months (Wood et al. 2008a) and with results of a meta-
analysis of 12 observational studies that reported a similar
risk of ARV resistance in IDUs and non-IDUs (Werb et al.
2010). In the ART era, co-infection with hepatitis B and C
has been associated with increased mortality (Chen et al.
2009; Chun et al. 2012). The large proportion of co-
infection among IDUs treated in the programme did not
allow us to examine the independent effect of hepatitis on
patient mortality. Nevertheless, hepatic and non-AIDS-
related cancer, including hepatic cancer, were responsible
forthemajorityofnon-AIDS-related deaths,suggestingthat
the burden of disease related to hepatitis infection is
important in this setting. Future models of HIV care that
considerhepatitisBandCco-infection-relatedissuessuchas
ART-related hepatotoxicities, choice of ART regimen and
access to hepatitis C treatments [despite signiﬁcant chal-
lenges regarding hepatitis C treatments, including expense,
complexity,variablesuccessratesandsigniﬁcantsideeffects
(Dou et al. 2010)], may further decrease non-AIDS-related
mortality in HIV programmes.
Conclusions
Mortality associated with HIV disease was higher during
the ﬁrst 6 months of treatment and among late presenters,
highlighting the need to improve both early access to HIV
testing and earlier start of therapy. Patients with history of
IDU experienced mortality and attrition rates similar to
other patients in this programme, ﬁndings that support the
feasibility of achieving satisfactory treatment outcomes in
this high-risk group.
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